1. Generics Bulletin
  2. >>Products

Amneal Delivers On Biosimilars Ambitions With Neupogen Rival

Company Also Reveals Plans For 20-30 Generics Launches In 2022

 
• By Akriti Seth

Amneal has laid out its plans to enter the US biosimilars market after receiving FDA approval for its first biosimilar, a Neupogen rival known as Releuko (filgrastim-ayow) that was developed with partner Kashiv Biosciences. Amneal also intends to launch two more biosimilars soon, along with 20-30 generics launches planned in 2022. 

Growth
Amneal plans to grow on the back of new generics and biosimilar launches and pending approvals • Source: Alamy

Amneal Pharmaceuticals, Inc. has announced receiving US Food and Drug Administration approval for its first biosimilar, a Neupogen rival that will be marketed under the name Releuko (filgrastim-ayow). Co-CEOs Chirag and Chintu Patel commented, “The US approval of our first biosimilar is a very significant milestone for Amneal.”

Amneal developed Releuko, indicated to treat neutropenia commonly experienced by patients undergoing chemotherapy, in collaboration with Chicago-based Kashiv Biosciences

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

More from Generics Bulletin